Loss of efficacy of biological therapies in psoriatic patients is a well-known event. Biological switching is common in clinical practice, especially in TNF-α and IL-12/23 inhibitors treatment1,2 . Recently, anti-IL-17A drugs such as secukinumab have provided a new therapeutic opportunity This article is protected by copyright. All rights reserved.
Efficacy and safety of switching to ixekizumab in secukinumab nonresponder psoriatic patients: results from a multicenter experience
Amerio, P;
2019-01-01
Abstract
Loss of efficacy of biological therapies in psoriatic patients is a well-known event. Biological switching is common in clinical practice, especially in TNF-α and IL-12/23 inhibitors treatment1,2 . Recently, anti-IL-17A drugs such as secukinumab have provided a new therapeutic opportunity This article is protected by copyright. All rights reserved.File in questo prodotto:
File | Dimensione | Formato | |
---|---|---|---|
bjd1547.pdf
Solo gestori archivio
Tipologia:
PDF editoriale
Dimensione
194.35 kB
Formato
Adobe PDF
|
194.35 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.